Glaukos Corporation

GKOS · Medical Instruments · $9.7B
Powering up
GKOS
$163.81
▲ +1.48%
09/18 O 160.60 H 163.85 L 159.01 C 163.81 ▲ +1.48%
Vol 1.5M RS 91
RS rating91
Now vs pivot (%)−14.51%
Tightening (ATR ratio)0.80×
Volume dry-up0.71×
Up/down volume, net0.14
From 52-week high15%
forming
Previous breakout trailed out ▲ +12.75% in Jul
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 4.2 weeks and fell 17% from its ceiling at its deepest. The pivot is $191.62, and the stock closed 14.5% below it. Its relative strength rating is 91.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
  1. Earningstentativein 40d
    Quarterly earnings
    Oct 28, 2026
Flagged by the market sweep
GappedTape · 2026-09-11
-5.2%

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?Zacks Investment Research · 2026-09-01

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Glaukos Corporation (GKOS) — The Tape